Vol 58, No 4 (2024)
Editorial Note
Published online: 2024-08-28

open access

Page views 314
Article views/downloads 178
Get Citation

Connect on Social Media

Connect on Social Media

EDITORIAL NOTE

Neurologia i Neurochirurgia Polska

Polish Journal of Neurology and Neurosurgery

2024, Volume 58, no. 4, pages: 353–356

DOI: 10.5603/pjnns.101744

Copyright © 2024 Polish Neurological Society

ISSN: 0028-3843, e-ISSN: 1897-4260 Gdansk, Poland

Recent Bibliometrics of the Journal and Thank You to Our Reviewers

Zbigniew K. Wszolek1Łukasz Stolarczyk2Jarosław Sławek3
1Co-Editor-in-Chief, Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, United States
2Journal Administrator, Via Medica, Gdansk, Poland
3Co-Editor-in-Chief, Department of Neurological-Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk,

Address for correspondence: Zbigniew K. Wszolek, M.D., Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Rd, Jacksonville, FL 32224, USA; e-mail: wszolek.zbigniew@mayo.edu

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Both Clarivate™ and Elsevier recently released their journal bibliometric measurements. We are incredibly pleased to report that the Impact Factor (IF) reported by Clarivate™ of the Neurologia i Neurochirurgia Polska (also known as Polish Journal of Neurology and Neurosurgery, PJNNS) remains stable at 2.9 (Fig. 1, bars). In post-COVID-19 times, many highly cited journals were not able to maintain their IF score. The IF score for 2023 was calculated by taking the number of citations in 2023 of all items published in PJNNS in 2021 and 2022, including editorial notes, invited editorials, invited review articles, review articles, research papers, short communications, and letters to the editors and dividing that number by the total number of research papers, short communications, invited reviews, and review articles published in 2021 and 2022 years. However, the PJNNS journal has moved from Q3 level in 2022 to Q2 level in 2023 (Fig. 1, line). This is an important achievement. Currently, PJNNS is ranked 99/277 in Web of Science™ category, “Clinical Neurology”.

Figure 1. PJNNS’s Impact Factor (IF) Trend. Despite the same value of IF for 2022 and 2023 (IF = 2.9, bars), PJNNS has achieved higher ranking in journal IF (JIF) assessment (line). PJNNS has moved from Q3 to Q2 (JIF percetile rose from 45.5 in 2022 to 64.4 in 2023). Source: JCR Edition 2024 by Clarivate Analytics

Elsevier’s Scopus CiteScore™ (CS) of PJNNS has risen from 3.4 in 2022 to 4.2 in 2023 (Fig. 2). Scopus CS measures the bibliometric status of the journal differently than Clarivate™ IF. Calculations of current CS include a period of 4 years, including citations of the calculation’s year and count all published items (ie, editorial notes, invited editorials, invited review articles, review articles, research papers, short communications, and letters to the editors). The steady increase of PJNNS’s Scopus CS is very encouraging.

Figure 2. PJNNS’s Elsevier Scopus CiteScore™ (CS) Trend. CS represents a key bibliometric parameter measuring the journal’s standing and is calculated from the Scopus database. CS has demonstrated a systematic growth for PJNNS. Current CS is based on the number of citations received by the journal in the last 4 years (including the calculation year) divided by the number of documents published (all items) in the journal in those 4 years. Based on this measure, PJNNS has been ranked 125/551 (77th percentile) in the Scopus category, “Medicine/Surgery”, and 187/400 (53rd percentile) in the category, “Medicine/Neurology (Clinical)”. Source: Data from Scopus database

Moreover, the PJNNS Immediacy Index (ImI) calculated by Clarivate™ has also substantially improved (Fig. 3). ImI counts the citations to the journal’s published items in the current year. Thus, it represents the bibliometric measure of relevance of published articles in the same year. The ImI of PJNNS has systematically increased from 0.3 in 2019 to 1.4 in 2023.

Figure 3. PJNNS’s Immediacy Index (ImI) Trend. ImI counts all citations in the current year to the journal’s content in this same year. Journals that have a high ImI attract citations rapidly.
Source: JCR Edition 2024 by Clarivate Analytics

Table 1 presents the 11 most cited articles in 2021 and 2022 that contributed to PJNNS’s 2023 IF (3 had an equal number of citations). Seven were research papers and 4 were review articles. They dealt with a wide-spectrum of neurologic conditions, including stroke, neurologic manifestations of COVID-19, and movement disorders.

Table 1. Eleven most cited manuscripts published in PJNNS that contributed to calculation of 2023 Journal Impact Factor

First author

Title

Year
published

Type

Reference

Madetko N. et al.

Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns

2022

Research Paper

[1]

Bratosiewicz-Wasik J.

Neuro-COVID-19: an insidious virus in action

2022

Review

[2]

Gueye T. et al.

Early post-stroke rehabilitation for upper limb motor function using virtual reality and exoskeleton: equally efficient in older patients

2021

Research Paper

[3]

Peycheva M. et al.

The role of fibrinogen in acute ischaemic stroke

2021

Research Paper

[4]

Alster P. et al.

Neutrophil-to-lymphocyte ratio (NLR) at boundaries of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)

2021

Research Paper

[5]

Czarnowska A. et al.

Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience

2021

Research Paper

[6]

Przytula F. et al.

Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome

2021

Research Paper

[7]

Wnuk M. et al.

Neurological symptoms in hospitalized patients with COVID-19 and their association with in-hospital mortality

2021

Research Paper

[8]

Nojszewska M. et al.

COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society*

2021

Review

[9]

Milanowski Ł. et al.

Genetics of Parkinson’s disease in the Polish population*

2021

Review

[10]

Mazurkiewicz-Bełdzińska M. et al.

Use of cannabidiol in the treatment of epilepsy*

2022

Review

[11]

The status of PJNNS would never be possible without the contribution of authors and tireless work of the Journal’s peer reviewers. The editors of PJNNS and the administrative staff of our Journal’s publisher, Via Medica, are incredibly grateful to our reviewers for their generous commitment to the Journal. The editors truly understand the effort and time required to review the submitted articles. Thus, as a small token of appreciation, we present here a list of our dedicated reviewers (Table 2). We highlighted in green those reviewers who provided 3 or more reviews in 2023.

Table 2. Alphabetical list of PJNNS reviewers in 2023. Names of reviewers who provided three or more reviews appear in green

First name

Last name

Monika

Adamczyk-Sowa

Piotr

Alster

Wojciech

Ambrosius

Mohamed

Arnaout

Yasuhiko

Baba

Anna

Barczak

Halina

Bartosik-Psujek

Joanna

Bielewicz

Magdalena

Boczarska-Jedynak

Robert

Bonek

Magdalena

Bosak

Daniel

Broderick

Waldemar

Brola

Askiel

Bruno

Sławomir

Budrewicz

Krzysztof A.

Bujarski

Kamil

Chwojnicki

Victor

Constantinescu

Arthur

Cukiert

Jeremy

Cutsforth-Gregory

Elliot

Dimberg

Tomas

Dobrocky

Brynn

Dredla

Jarosław

Dulski

Judith

Dunmore

Stephen

English

Olga

Fermo

Andrzej

Friedman

Shinsuke

Fujioka

Tomasz

Gabryelewicz

Dariusz

Gąsecki

Neil

Graff-Radford

Mario

Habek

Michael

Heckman

Maria

Hoeltzenbein

Josephine

Huang

Lauren

Jackson

Jeremiasz

Jagiełła

Sergiusz

Jóźwiak

Alicja

Kalinowska-Łyszczarz

Karolina

Kania

Katarzyna

Kapica-Topczewska

Bartosz

Karaszewski

Michał

Karliński

Radosław

Kaźmierski

Magdalena

Koszewicz

Tomasz

Kotwicki

Grzegorz

Kozera

Ewa

Krzystanek

Wirginia

Krzyściak

Alina

Kułakowska

Iwona

Kurkowska-Jastrzębska

Anetta

Lasek-Bal

Michelle

Lin

Marta

Lipowska

Alfonso S.

Lopez Chiriboga

Tomasz

Lyson

Beata

Łabuz-Roszak

Dariusz

Łątka

Tomasz

Mandat

Marek

Mandera

Zenon

Mariak

Iris

Marin Collazo

James F.

Meschia

Sławomir

Michalak

Erik

Middlebrooks

Grzegorz

Miękisiak

Łukasz

Milanowski

David

Miller

Dagmara

Mirowska-Guzel

Karthik

Muthusamy

Eric W.

Nottmeier

Julia

Nowak

Simy

Parikh

Mikolaj

Pawlak

Jukka

Peltola

Ronald

Pfeiffer

Anna

Pokryszko-Dragan

Mercedes

Prudencio

Maciej

Racinowski

Maciej

Radek

Vedantam

Rajshekhar

Jill

Rau

Konrad

Rejdak

Bertold

Renner

Maria

Respondek-Liberska

Joao

Ricardo

Hector

Robles

Radosław

Rola

Jacek

Rożniecki

Monika

Rudzińska-Bar

Iwona

Sarzyńska-Długosz

Katarzyna

Sawczyńska

Michał

Schinwelski

Thomas G.

Schreiner

Zbigniew

Serafin

Mariusz

Siemiński

Halina

Sienkiewicz-Jarosz

Joseph

Sirven

Emilia

Sitek

Joanna

Siuda

Matej

Skorvanek

Agnieszka

Słowik

Jerzy

Słowiński

Piotr

Sobolewski

Michał

Sobstyl

Alexandra E.

Soto Pina

Mariusz

Stasiołek

Jacek

Staszewski

Barbara

Steinborn

Piotr

Szczudlik

Jacek

Szczygielski

Stanisław

Szlufik

Tomasz

Szmuda

Paweł

Tacik

Philip

Tipton

Ryan

Uitti

Marta

Waliszewska-Prosół

Lindsy

Williams

Joanna

Wojczal

Zyta

Wojszel

Sevil

Yasar

Joanna

Zajkowska

Beata

Zakrzewska-Pniewska

Marta

Zawadzka

Daniel

Zielonka

Jarosław

Zygierewicz

Wioletta

Żukowicz

Kamila

Żur-Wyrozumska

References

  1. Madetko N, Migda B, Alster P, et al. Platelet-to-lymphocyte ratio and neutrophil-tolymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns. Neurol Neurochir Pol. 2022; 56(2): 148–155, doi: 10.5603/PJNNS.a2022.0014, indexed in Pubmed: 35118638.
  2. Bratosiewicz-Wąsik J. Neuro-COVID-19: an insidious virus in action. Neurol Neurochir Pol. 2022; 56(1): 48–60, doi: 10.5603/PJNNS.a2021.0072, indexed in Pubmed: 34642927.
  3. Gueye T, Dedkova M, Rogalewicz V, et al. Early post-stroke rehabilitation for upper limb motor function using virtual reality and exoskeleton: equally efficient in older patients. Neurol Neurochir Pol. 2021; 55(1): 91–96, doi: 10.5603/PJNNS.a2020.0096, indexed in Pubmed: 33314016.
  4. Peycheva M, Deneva T, Zahariev Z. The role of fibrinogen in acute ischaemic stroke. Neurologia i Neurochirurgia Polska. 2021; 55(1): 74–80, doi: 10.5603/pjnns.a2020.0094.
  5. Alster P, Madetko N, Friedman A. Neutrophil-to-lymphocyte ratio (NLR) at boundaries of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS). Neurol Neurochir Pol. 2021; 55(1): 97–101, doi: 10.5603/PJNNS.a2020.0097, indexed in Pubmed: 33315235.
  6. Czarnowska A, Brola W, Zajkowska O, et al. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience. Neurologia i Neurochirurgia Polska. 2021; 55(2): 212–222, doi: 10.5603/pjnns.a2021.0031.
  7. Przytuła F, Błądek S, Sławek J. Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome. Neurologia i Neurochirurgia Polska. 2021; 55(3): 310–313, doi: 10.5603/pjnns.a2021.0036.
  8. Wnuk M, Sawczyńska K, Kęsek T, et al. Neurological symptoms in hospitalised patients with COVID-19 and their association with in-hospital mortality. Neurologia i Neurochirurgia Polska. 2021; 55(3): 314–321, doi: 10.5603/pjnns.a2021.0039.
  9. Nojszewska M, Kalinowska A, Adamczyk-Sowa M, et al. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurol Neurochir Pol. 2021; 55(1): 8–11, doi: 10.5603/PJNNS.a2021.0016, indexed in Pubmed: 33555604.
  10. Milanowski Ł, Ross O, Friedman A, et al. Genetics of Parkinson’s disease in the Polish population. Neurologia i Neurochirurgia Polska. 2021; 55(3): 241–252, doi: 10.5603/pjnns.a2021.0013.
  11. Mazurkiewicz-Bełdzińska M, Zawadzka M. Use of cannabidiol in the treatment of epilepsy. Neurol Neurochir Pol. 2022; 56(1): 14–20, doi: 10.5603/PJNNS.a2022.0020, indexed in Pubmed: 35211946.